Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 2 · 28.6%High 0 · 0%

Avalglucosidase alfa vs alglucosidase alfa

Change from baseline in 6MWT (metres) · adults with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Moderate

Avalglucosidase alfa vs alglucosidase alfa

FVC (% predicted) Change from baseline · adults with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Moderate

Avalglucosidase alfa vs alglucosidase alfa

Infusion reactions · adults with LOPD

Avalglucosidase alfa showed no clear difference in infusion reactions compared with alglucosidase alfa (low certainty).

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
RR 0.78 [0.42, 1.45]
1 study · 100 participants
Low

Avalglucosidase alfa vs alglucosidase alfa

Need for respiratory support · adults with LOPD

The review found no eligible studies for this question.

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avalglucosidase alfa vs alglucosidase alfa

Use of a walking aid / wheelchair · adults with LOPD

The review found no eligible studies for this question.

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avalglucosidase alfa vs alglucosidase alfa

QoL · adults with LOPD

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Low

Avalglucosidase alfa vs alglucosidase alfa

Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · adults with LOPD

Avalglucosidase alfa showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa (low certainty).

1 finding from 1 review

Enzyme replacement therapy for late‐onset Pompe disease 2023 · Cochrane Headline outcomes only
RR 0.92 [0.61, 1.4]
1 study · 100 participants
Low